Zydus Cadila, one of
India's leading healthcare groups, provides total healthcare solutions ranging
from formulations, active pharmaceutical ingredients, biologicals, herbals,
animal healthcare products to cosmeceuticals. Headquartered in Ahmedabad, the
group is spearheaded by Chairman and Managing Director, Mr. Pankaj R. Patel.
Established in 1952, as Cadila Laboratories, the group's association with the
industry spans over five decades. Founded by the Late Mr. Ramanbhai B. Patel,
Cadila grew to become the second largest Indian pharmaceutical company in the
1990s. In 1995, the group restructured its operations and emerged with a new
identity under the aegis of the Zydus group. From a Rs. 2 billion start-up
company in 1995, today, Zydus Cadila is an integrated player in the industry
with a turnover exceeding Rs. 15 billion.
The key to the group's success has been in its commitment to accelerate growth,
globalize business operations and lead in a highly competitive environment. The
new product launches coupled with therapy management and brand management
skills have helped sharpen Zydus Cadila's competitive edge in the Indian
pharmaceutical industry. The group's strategic focus has been on fast growing
therapeutic segments such as cardiovascular, gastrointestinal, women's
healthcare, respiratory, pain management, anti-infectives, biologicals and CNS.
In the participated segments, Zydus Cadila holds a commanding position in the
Indian pharma industry sweepstakes. It is the leading player in the
cardiovascular, gastrointestinal and women's healthcare segments. It is No. 2
player in the respiratory segment with considerable strengths in the
anti-infective and pain management segments in India. Zydus Cadila also has an
extensive marketing network with one of the strongest distribution networks in
the industry.
The group has a global presence of in over 43 countries. It has operations in
U.S., Europe and Latin America through its subsidiaries Zydus Pharmaceuticals
(U.S.A.) Inc., Zydus Healthcare LLC, Zydus France SAS and Zydus Healthcare
Brasil Limited.
With commitment to partners, the group has also forged win-win alliances with
several global pharma majors such as Altana Pharma, Mayne Pharma, Mallinckrodt,
Schering AG, Boerhinger Ingelheim, Zambon, Berna Biotech, to mention a few.
Successful operations in the domestic and international market and strengths in
research are backed by a strong infrastructure network. The group has eight
state-of-the-art vertically integrated manufacturing facilities spread across 4
states. The formulation manufacturing plant at Moraiya about 15 kms from
Ahmedabad is the largest of its kind at a single location in Asia and has been
approved by the USFDA and other leading global regulatory bodies of the world.
The group also has USFDA approved API plants at Dabhasa near Vadodara and
Ankleshwar in Gujarat.
The formulations plant at Moraiya also has two dedicated units to manufacture
vaccines. The group manufactures Vaxirab, Purified Duck Embryo Vaccine (PDEV),
and a new generation vaccine for rabies, developed in technical collaboration
with Berna Biotech of Switzerland. The vaccine has been approved by the FDA and
DCGI of India. Clinical studies in the vaccine have established immunological
efficacy (100% sero-conversion). The plant has installed capacity of 2.4
million doses/annum. In addition to this, the group also manufactures
indigenously developed VacTyph / Purified Vi Capsular Polysaccharide Typhoid
Vaccine. VacTyph is safe and can be used for babies who are two years and
above. The master seed strain has been certified by the WHO surveillance
centre, SSI of Denmark and approved by NCA of India. The vaccine has been
approved by FDA and the DCGI of India. The plant has installed capacity of 6.0
million dose/annum. The production and Quality Control parameters of Vaxirab
(Purified Duck Embryo Vaccine (PDEV) and VacTyph conform to WHO guidelines.
Zydus Cadila has a team of over 500 research professionals spearheading its
research programme at the Zydus Research Centre. At the Zydus Research Centre,
the dedicated research arm of the group of more than 200 scientists are engaged
in the NCE research. The Zydus Research Centre is also working in the areas of
New Chemical Entities, New Drug Delivery Systems and Biotechnology.
The company's vision is to be a global research driven company by 2020. It
plans to achieve sales of $400 million by 2006 and be a top ten global generic
company with a strong R&D pipeline and sales in excess of $1 billion by
2010.
In its pursuit of these goals, the group is supported by a team of 6000 people
comprising professionals, research scientists, medical advisors and workers.
Poised for a higher growth and more success in the coming years, Zydus Cadila
draws confidence from its proven track record which both prescribes and
projects a vibrant and soundly based future.
Address